Myelodysplastic Syndromes Debate: Should Molecular Genetics Guide the Decision for Allogeneic Transplant - Pro

Allogeneic transplantation is the only curative therapy for the Myelodysplastic Syndromes (MDS). Older prognostic systems such as the IPSS and IPSS-R can help determine the appropriateness of allogeneic stem cell transplantation (SCT), however the incorporation of molecular genetic profiling in MDS can allow us to refine our decision making process – not only to help decide who should undergo SCT, but how they should undergo SCT.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research